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Abstract
Background: Family history of breast cancer is associated with an increased risk of contralateral breast cancer
(CBC) even in the absence of mutations in the breast cancer susceptibility genes BRCA1/2. We compared
quality-adjusted survival after contralateral prophylactic mastectomy (CPM) with surveillance only (no CPM)
among women with breast cancer incorporating the degree of family history.
Methods: We created a microsimulation model for women with first-degree, second-degree, and no family
history treated for a stage I, II, or III estrogen receptor (ER)-positive or ER-negative breast cancer at the ages
of 40, 50, 60, and 70. The model incorporated a 10-year posttreatment period for risk of developing CBC and/
or dying of the primary cancer or CBC. For each patient profile, we used 100,000 microsimulation trials to
estimate quality-adjusted life expectancy for the clinical strategies CPM and no CPM.
Results: CPM showed minimal improvement on quality-adjusted life expectancy among women age 50–60
with no or a unilateral first-degree or second-degree family history (decreasing from 0.31 to –0.06
quality-adjusted life-years (QALYs)) and was unfavorable for most subgroups of women age 70 with stage III
breast cancer regardless of degree of family history (range –0.08 to –0.02 QALYs). Sensitivity analysis
showed that the highest predicted benefit of CPM assuming 95 % risk reduction in CBC was 0.57 QALYs for
a 40-year-old woman with stage I breast cancer who had a first-degree relative with bilateral breast cancer.
Conclusions: Women age 40 with stage I breast cancer and a first-degree relative with bilateral breast cancer
have a QALY benefit from CPM similar to that reported for BRCA1/2 mutation carriers. For most subgroups of
women, CPM has a minimal to no effect on quality-adjusted life expectancy, irrespective of family history of
breast cancer.
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Background
Despite the minimal survival benefit of contralateral
prophylactic mastectomy (CPM) and a declining incidence
of contralateral breast cancer (CBC) [1] since 1998, the
frequency of CPM has increased in the United States
among women with sporadic, unilateral breast cancer
[2, 3]. The reasons for the increased use of CPM include
increased national rates of mastectomy compared to
breast conserving surgery [2], the desire to reduce the risk
of CBC, to improve survival, and to have peace of mind
[4]. Although CPM may improve health outcomes for par-
ticular subgroups, specifically younger women with a
BRCA1/2 mutation, hereditary mutations account for only
5–10 % of cancers [5]. The additional surgery may thus be
unnecessary for the majority of women diagnosed with
breast cancer [6, 7].
Several decision analysis models have been developed
for comparing CPM with surveillance only (no CPM)
for the outcomes of life expectancy, quality-adjusted
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life expectancy, and cost-effectiveness [7–10]. For high-
risk groups (i.e., women with a BRCA1/2 mutation),
CPM has been shown to be cost-effective compared
with surveillance in terms of life expectancy [11]. In
women without a BRCA1/2 mutation, Portschy et al. [7]
showed a less than 1 % 20-year survival benefit due
to CPM for patients with stage I breast cancer, with
an even smaller benefit for patients with stage II breast
cancer.
Family history of breast cancer is considered to be
an important risk factor for developing CBC even among
women without mutations in the BRCA1/2 breast cancer
susceptibility gene [12, 13]. As the degree of family
history of breast cancer increases, so does the risk of
CBC. Noncarriers of a BRCA1/2 mutation with any
first-degree relative with bilateral breast cancer have
CBC risk levels similar to those of BRCA1/2 mutation
carriers [14]. Several epidemiologic studies have shown
that the frequency of CPM is higher among women
with a family history of breast cancer [15, 16] and among
women undergoing genetic testing even if they test
negative for a mutation in BRCA1/2 [17, 18]. How-
ever, the survival benefit of CPM in relation to family
history of breast cancer, taking into consideration age,
stage, and estrogen receptor (ER) status, has not been
determined.
The aim of this study was to determine the impact
of CPM on 20-year overall and disease-free survival and
quality-adjusted life expectancy for women without a BR
CA1/2 mutation, taking into consideration age at diagno-
sis, disease stage, ER status, and degree of family history
of breast cancer. We hypothesized that women with a
higher degree of family history would experience the




We developed an individual-level state-transition model
to simulate the long-term survival outcomes of women
who undergo CPM and women who do not following a
unilateral mastectomy or breast-conserving surgery of
the primary breast cancer (Fig. 1). The model assumes a
population of women with early-stage breast cancer with-
out a hereditary breast cancer syndrome. Our analysis
was conducted over a lifetime horizon, beginning at age
40, 50, 60, or 70 following treatment of the primary
cancer. We assumed that patients received equivalent,
standard treatment for the primary breast cancer in the
CPM and non-CPM strategies. Since total complication
rates for either unilateral or bilateral mastectomy with
reconstruction are <2.5 % we did not consider them
in the model [19]. Ten-year and 20-year overall and
disease-free survival rates were determined by estimating
life expectancy and disease-free life expectancy, respec-
tively, over the corresponding time periods.
Each year, after treatment, the women may remain in
a cancer-free (survivor) state, die of the primary cancer,
develop a CBC, or die of other causes. The risk of CBC
was incorporated into a 10-year period from the time of
initial treatment. A 10-year period was chosen to look
for the first event of a CBC because this time frame is
sufficient to capture events in the natural progression of
the disease [20]. If a CBC develops, the patient has an
increased risk of dying from breast cancer, since the
risks of dying from the primary and secondary cancers
are considered additive [21]. Analogous to the 10-year
risk period for development of a CBC or death from the
primary cancer, patients are assumed to be at risk of
death from the CBC for 10 years following its develop-
ment and this annual risk is incorporated into the model
with a 10-year post-CBC development risk period. Once
the initial 10-year risk period for the index breast cancer
ends, the overall mortality risk decreases because only
the risk of dying from the CBC is considered.
We categorized patients who survive for 10 years with-
out developing a CBC or since developing a CBC as long-
term survivors. Long-term survival risks approach those
of the general population after 10 years [20] and were
considered the same for both the CPM group and the no-
CPM group. An individual-level model was chosen for
ease in tracking the length of time since treatment for the
primary cancer or development of a CBC for precise
estimation of the risk of death. We created the model
using the decision analysis software TreeAge Pro 2014
(TreeAge Software, Inc., Williamstown, MA, USA).
Probability estimates
Although many clinical characteristics, such as tumor
grade or ER status, may influence the growth rate and the
metastatic potential of small tumors [22], the stage of a
primary tumor at diagnosis is a key indicator of prognosis,
particularly for early-stage cancers. Thus, our model incor-
porates annual breast cancer-specific mortality rates ex-
trapolated from 10-year disease-specific risks of death for
patients with stage I–III cancers that were derived from
the relative survival curves in the Surveillance, Epidemi-
ology, and End Results database as presented in Portschy
et al. [7]. Age-specific mortality rates were obtained from
US life tables [23].
The annual risk of developing a CBC is thought to be
0.5–0.75 % [6, 24–29]. However, this may be an overes-
timate due to the now widespread use of adjuvant sys-
temic therapy. Adjuvant hormonal therapies for women
with ER-positive tumors, including tamoxifen for premen-
opausal women and aromatase inhibitors for postmeno-
pausal women, have been shown to reduce CBC risk by as
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much as 50 % [2, 3]. Thus, the risk of CBC is lower for
patients with ER-positive than ER-negative breast cancers.
In a meta-analysis performed by the Early Breast Cancer
Trialists’ Collaborative Group, the 15-year incidence of
CBC was 6.5 % in women with ER-positive disease who
were randomized to tamoxifen therapy and was appro-
ximately 7.1 % in women with ER-negative disease regard-
less of use of tamoxifen [30]. These rates were converted
to annual probabilities, assuming the incidence rates were
constant over the 15-year interval, resulting in 0.4 %
and 0.5 % annual risks of developing CBC for ER-positive
and ER-negative patients, respectively. We used these
estimates to determine the ratio of the risk of developing
CBC in ER-negative patients to the risk in ER-positive
patients.
The risks of CBC according to family history are an
average annual risk of developing CBC estimated from a
population-based case–control study of women without
BRCA mutation who had a primary breast cancer in four
US cancer registries. The study population may have
included women who were treated with a unilateral
mastectomy or breast-conserving surgery followed by
radiation and/or chemotherapy [13].
To incorporate both ER status and family history into
the risk for developing CBC, we assumed that the aver-
age risk for each degree of family history (none, second-
degree relative, first-degree relative with unilateral breast
cancer, and first-degree relative with bilateral breast
cancer) is a weighted average of risks for patients with
and ER-negative tumors. Then, using the proportions of
ER-positive and ER-negative tumors, estimated to be 75 %
and 25 %, respectively [12], and the ratio of average CBC
risks according to ER status (Table 1), we estimated the
risk for developing CBC for patients with ER-negative
tumors and patients with ER-positive tumors and at vary-
ing degrees of family history.
The stage distribution of a CBC was derived from a
study of the Oregon State Cancer Registry database by
Quan et al. [21]. In that database, 9 years of patient cases
of breast cancer were queried and over 90 % of CBCs
were determined to be early stage. We estimated that
the probabilities of developing stage I, II, III, and IV
CBC were 66 %, 25 %, 5 %, and 4 %, respectively. The
risk of death associated with a CBC was estimated to be
the same as the risk of death associated with a primary
cancer of the same stage and was added to the risk asso-
ciated with the primary breast cancer. Patients were
considered at risk for developing CBC within 10 years
after treatment of the primary breast cancer.
Utility estimates
We incorporated quality of life for each health state
using estimates of utilities reported in the literature
[8, 31]. Utilities typically measure quality of life on a 0–1
scale anchored by death and perfect health. Reduced qual-
ity of life is associated with treatment and disease health
states [31]. The impact of each treatment strategy was
thus measured in quality-adjusted life years (QALYs),
which are years lived equivalent to perfect health. We
identified two primary health states— unilateral mastec-
tomy or breast-conserving surgery (no CPM), and bilateral
mastectomy involving a CPM—for which utility adjust-
ments needed to be made. We assumed the initial utility
of unilateral mastectomy or breast-conserving surgery to
Fig. 1 Markov model of outcomes of CPM and no CPM. Women in each Markov state (no CBC, CBC stages I, II, III, and IV) can transition to the
“long-term survivor” health state after 10 years (cycles) without a breast cancer event or death and to the terminal states “death from other
causes” and “death from breast cancer” during each cycle. CBC states outlined in red are health states with transition probabilities dependent on
stage of CBC. CPM contralateral prophylactic mastectomy, ER estrogen receptor, CBC contralateral breast cancer (Color figure online)
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be 0.90 and the initial utility of bilateral mastectomy to be
0.70, because of the greater initial postsurgery disutility
associated with bilateral mastectomy. If no CBC deve-
loped during the first year, in years 2–5 after surgery
the utilities were assumed to be 0.79 for both health
states; beyond year 5, the utility for both health states
was assumed to be 0.84. If a CBC developed at any
time during the 10-year period, the utility value was
changed to 0.73 for 2 years following the CBC diag-
nosis. Between years 2 and 5, the utility value for the
CBC health state was increased to 0.79. As with the
primary (no-CBC) health state, this value was in-
creased to 0.84 beyond year 5.
Sensitivity analysis
We conducted a sensitivity analysis of base case para-
meter estimates of reductions in the risk of developing
CBC after CPM. The variable means and ranges were
established on the basis of published estimates (Table 1).
For our base-case analysis (Tables 2, 3, 4, 5), we estimated
that CPM reduces the risk of developing CBC by appro-
ximately 95 % [2, 21, 32, 33]. In our sensitivity analysis,
we used a CBC risk reduction in the range of 75–100 %
for each degree of family history. To perform a sensitivity
analysis on the utility values, we conducted the sensitivity
analysis of CBC risk and CPM-associated risk reduction
with the utility associated with each health state set to 1
Table 1 Base Case Probabilities, Utilities, and Ranges Used in Sensitivity Analysis
Variable Base Case Range Reference
Annual risk of CBC [13]
No family history of breast cancer 0.0047 0.0041–0.0052
Second-degree relative only 0.0061 0.0470–0.0900
First-degree relative, unilateral 0.0090 0.0063–0.0121
First-degree relative, bilateral 0.0168 0.0088–0.0330
BRCA 1/2 mutation carriers 0.0184 0.0160–0.0213
ER-negative/ER-positive risk ratio 1.25 1.10–2.00 [6, 7, 12, 13, 24–30]
CBC risk reduction after CPM 0.95 0.75–1.00 [2, 21, 32, 33]










Risk of dying of other causes Age specific [23]
[8, 31]
First year after treatment
CPM 0.70 0.41–0.95
No CPM 0.90 0.87–1.00
No CBC
Years 2-5 0.79 0.45–1.00
Year 6 and beyond 0.84 0.77–1.00
CBC
New CBC 0.73 0.58–1.00
Years 2-5 0.79 0.45–1.00
Year 6 and beyond 0.84 0.77–1.00
Long-term survivor 0.84 0.77–1.00
CPM contralateral prophylactic mastectomy, CBC contralateral breast cancer
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(i.e., no health decrements in the model), resulting in life
expectancy as the outcome. In addition, we conducted a
threshold analysis of the utility associated with CPM
during the year immediately following the surgery. In the
probabilistic sensitivity analysis, to evaluate uncertainty in
the model parameters, the mean and range were used to
calculate the parameter distribution values. We assumed
a beta distribution for all probabilities, a table distribution
for tumor stage based on the frequency, and a gamma dis-
tribution for the risk ratio of ER-negative to ER-positive,
and performed 10,000 Monte Carlo simulations.
Results
Effect of CPM on life expectancy by degree of family
history of breast cancer
CPM was associated with gains (0.02–0.82 years) in life
expectancy for all patient subgroups (Table 2). Greater
benefits were seen in patients age < 60, ER-negative
status, disease stage I or II, and having a first-degree
family history of breast cancer, especially with bilateral
breast cancer. The benefits of CPM decreased in patients
with characteristics associated with a greater risk of dying
of primary breast cancer or other causes: higher disease
stage and older age.
After quality-of-life adjustments were incorporated,
women age 40–50 with a first-degree relative with breast
cancer tended to have a positive benefit with CPM (Fig. 2).
However, the benefit was minimal to negative for those
with either no or a second-degree family history or stage
III disease. CPM had an overwhelmingly minimal to nega-
tive benefit for women age 60–70 with stage I–III disease
and no family history of breast cancer. Women age 70
with stage III disease had a negative benefit from CPM
regardless of the degree of family history of breast cancer.
For the 40–70 age range, the benefit of CPM compared
with no CPM decreased from 0.12 to –0.08 to QALYs for




No Family History Breast Cancer in a
Second-Degree Relative
Breast Cancer in a First-Degree Relative
Unilateral Bilateral
Age (years) ER Status Stage No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ
40 Positive I 41.43 41.63 0.21 41.37 41.63 0.26 41.25 41.63 0.38 40.93 41.61 0.68
40 Negative I 41.28 41.51 0.24 41.21 41.51 0.30 41.06 41.50 0.45 40.66 41.48 0.82
40 Positive II 32.85 32.99 0.14 32.80 32.98 0.18 32.69 32.98 0.28 32.43 32.97 0.54
40 Negative II 32.74 32.94 0.20 32.68 32.94 0.25 32.58 32.93 0.35 32.27 32.91 0.65
40 Positive III 18.55 18.63 0.08 18.53 18.63 0.10 18.49 18.63 0.14 18.37 18.62 0.25
40 Negative III 18.45 18.57 0.11 18.42 18.56 0.14 18.36 18.56 0.20 18.20 18.54 0.34
50 Positive I 32.27 32.43 0.15 32.22 32.42 0.20 32.13 32.42 0.29 31.90 32.41 0.51
50 Negative I 32.30 32.50 0.20 32.24 32.50 0.26 32.12 32.49 0.37 31.85 32.47 0.62
50 Positive II 25.97 26.10 0.12 25.94 26.09 0.16 25.87 26.09 0.23 25.69 26.08 0.39
50 Negative II 25.93 26.08 0.16 25.88 26.08 0.20 25.82 26.08 0.26 25.60 26.06 0.46
50 Positive III 15.13 15.18 0.05 15.11 15.18 0.07 15.08 15.18 0.10 14.99 15.18 0.19
50 Negative III 15.08 15.15 0.06 15.07 15.15 0.08 15.03 15.14 0.12 14.91 15.14 0.23
60 Positive I 23.84 23.93 0.09 23.82 23.93 0.11 23.76 23.93 0.17 23.61 23.92 0.31
60 Negative I 23.88 23.99 0.11 23.84 23.99 0.15 23.76 23.98 0.22 23.59 23.97 0.38
60 Positive II 19.39 19.47 0.08 19.36 19.47 0.11 19.32 19.47 0.14 19.19 19.46 0.27
60 Negative II 19.46 19.53 0.08 19.43 19.53 0.10 19.39 19.53 0.14 19.25 19.52 0.26
60 Positive III 11.92 11.96 0.03 11.91 11.96 0.04 11.89 11.96 0.07 11.83 11.95 0.13
60 Negative III 11.84 11.89 0.05 11.82 11.89 0.07 11.78 11.89 0.11 11.72 11.88 0.17
70 Positive I 16.14 16.19 0.05 16.13 16.19 0.06 16.09 16.19 0.09 16.02 16.18 0.17
70 Negative I 16.09 16.15 0.06 16.07 16.15 0.08 16.04 16.15 0.11 15.95 16.14 0.19
70 Positive II 13.50 13.53 0.04 13.49 13.53 0.05 13.45 13.54 0.08 13.39 13.53 0.14
70 Negative II 13.50 13.55 0.05 13.49 13.55 0.06 13.45 13.54 0.10 13.36 13.54 0.18
70 Positive III 8.78 8.79 0.02 8.77 8.79 0.02 8.75 8.79 0.04 8.72 8.79 0.07
70 Negative III 8.78 8.80 0.03 8.77 8.80 0.04 8.76 8.80 0.05 8.73 8.80 0.07
ER estrogen receptor, CPM contralateral prophylactic mastectomy, Δ, difference (CPM-No CPM); CBC risk reduction = 95% (base-case)
Davies et al. Breast Cancer Research  (2016) 18:93 Page 5 of 13
women with no family history of breast cancer, from 0.17
to –0.07 QALYs for women with only a second-degree
relative with breast cancer, from 0.31 to –0.06 QALYs for
women with a first-degree relative with unilateral breast
cancer, and from 0.65 to –0.02 QALYs for women with a
first-degree relative with bilateral breast cancer (Table 3).
For all age groups, women with ER-negative breast can-
cers had a greater QALY benefit from CPM (or less nega-
tive benefit for women age 60–70) than patients with
ER-positive breast cancers, irrespective of family history
(Fig. 3). A similar relationship was also observed for
patients with ER-negative versus ER-positive breast cancer
irrespective of stage of the primary cancer (Fig. 4).
Effect of CPM on CBC, overall survival, and disease-free
survival by degree of family history of breast cancer
A greater number of CBCs occurred in the group who
did not have CPM. With CPM, the overall range of the
rate of CBCs was reduced from 26–193 per 1000 women
to 1–11 per 1000 women (Table 4).
Generally, the prevention of CBC had greater survival
benefit for younger women. However, for women age 50
with stage I or II primary breast cancer there was the same
or slightly greater 10-year and 20-year survival benefit
associated with CPM compared with those age 40, irre-
spective of family history (Table 5). There may thus be an
additive effect between the breast cancer mortality risk
and increased background mortality risk at age 50 com-
pared with age 40. With the older age groups, however,
background mortality outweighed any CBC mortality risk.
For all age groups, the greatest reduction in the range
of the rates of CBC as a result of CPM occurred in
women with a higher degree of family history and with
ER-negative tumors (Table 4). The maximum 20-year
absolute overall survival rate benefit for CPM versus no
CPM was 0.36 % for women with no family history of




No Family History Breast Cancer in a
Second-Degree Relative
Breast Cancer in a First-Degree Relative
Unilateral Bilateral
Age (years) ER Status Stage No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ
40 Positive I 34.61 34.70 0.09 34.56 34.70 0.14 34.45 34.70 0.25 34.16 34.68 0.52
40 Negative I 34.48 34.60 0.12 34.43 34.60 0.17 34.28 34.59 0.31 33.92 34.57 0.65
40 Positive II 27.42 27.45 0.03 27.38 27.45 0.07 27.28 27.44 0.16 27.04 27.43 0.40
40 Negative II 27.33 27.41 0.08 27.28 27.41 0.13 27.18 27.40 0.23 26.89 27.39 0.50
40 Positive III 15.45 15.42 -0.03 15.42 15.42 0.00 15.38 15.41 0.03 15.28 15.41 0.14
40 Negative III 15.36 15.36 0.01 15.33 15.36 0.03 15.27 15.36 0.09 15.12 15.34 0.22
50 Positive I 26.92 26.97 0.05 26.88 26.97 0.09 26.79 26.96 0.17 26.58 26.95 0.38
50 Negative I 26.94 27.03 0.09 26.89 27.03 0.14 26.78 27.02 0.25 26.52 27.01 0.49
50 Positive II 21.65 21.66 0.02 21.62 21.66 0.05 21.55 21.66 0.11 21.38 21.65 0.27
50 Negative II 21.61 21.65 0.05 21.57 21.65 0.09 21.50 21.65 0.15 21.29 21.63 0.34
50 Positive III 12.57 12.52 -0.05 12.55 12.52 -0.03 12.52 12.52 0.00 12.43 12.52 0.08
50 Negative III 12.53 12.49 -0.04 12.51 12.49 -0.02 12.47 12.49 0.02 12.36 12.49 0.13
60 Positive I 19.85 19.84 -0.01 19.82 19.84 0.01 19.76 19.83 0.07 19.61 19.83 0.21
60 Negative I 19.87 19.88 0.01 19.83 19.88 0.05 19.76 19.88 0.12 19.58 19.87 0.28
60 Positive II 16.12 16.10 -0.02 16.10 16.10 0.00 16.06 16.10 0.04 15.93 16.09 0.17
60 Negative II 16.17 16.15 -0.02 16.15 16.15 0.00 16.10 16.15 0.05 15.97 16.14 0.17
60 Positive III 9.88 9.82 -0.06 9.87 9.81 -0.05 9.84 9.81 -0.03 9.78 9.81 0.03
60 Negative III 9.80 9.76 -0.04 9.79 9.76 -0.03 9.75 9.76 0.01 9.68 9.75 0.07
70 Positive I 13.38 13.34 -0.05 13.37 13.34 -0.03 13.33 13.33 0.00 13.25 13.33 0.08
70 Negative I 13.34 13.30 -0.03 13.32 13.30 -0.02 13.28 13.30 0.02 13.18 13.29 0.11
70 Positive II 11.18 11.12 -0.06 11.16 11.12 -0.05 11.13 11.12 -0.01 11.06 11.12 0.05
70 Negative II 11.18 11.13 -0.05 11.16 11.13 -0.03 11.12 11.13 0.01 11.03 11.12 0.09
70 Positive III 7.24 7.16 -0.08 7.24 7.16 -0.07 7.22 7.16 -0.06 7.18 7.16 -0.02
70 Negative III 7.24 7.17 -0.07 7.23 7.17 -0.06 7.22 7.17 -0.05 7.18 7.17 -0.01
ER estrogen receptor, CPM contralateral prophylactic mastectomy, Δ, difference (CPM-No CPM); CBC risk reduction = 95% (base-case)
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breast cancer, 0.46 % for women with only a second-
degree relative with breast cancer, 0.69 % for women
with a first-degree relative with unilateral breast cancer,
and 1.21 % for women with a first-degree relative with
bilateral breast cancer (Table 5, Fig. 2c). The maximum
20-year absolute disease-free survival rate benefit for
CPM versus no CPM was 3.73 % for women with no
family history of breast cancer, 4.76 % for women with
only a second-degree relative with breast cancer, 6.97 %
for women with a first-degree relative with unilateral
breast cancer, and 12.59 % for women with a first-degree
relative with bilateral breast cancer (Table 5, Fig. 2d).
Sensitivity analysis of differences in quality-adjusted life
expectancy by degree of family history of breast cancer
In our model, the risk of developing CBC varied accor-
ding to family history. The predicted absolute differences
in quality-adjusted life expectancy given the CBC risk
associated with the degree of family history and BRCA1/
2 mutation status are shown in Fig. 5. Greater benefits
of CPM were predicted for women with greater risk of
developing CBC. With the CBC risk reduction assumed
to be 100 %, the maximum absolute benefit for a 40-
year-old woman with stage I breast cancer was 0.61
QALYs, and the annual probability of developing a CBC
for the aforementioned woman with a first-degree rela-
tive with bilateral breast cancer was 1.68 %. In compari-
son, the maximum absolute benefit for a 40-year-old
woman with stage I breast cancer and BRCA1/2 muta-
tion was 0.72 QALYs, and the annual probability of
developing a CBC was 2.01 %. As expected, the benefit
of CPM decreased with age and stage. The maximum
absolute benefit for a 50, 60, or 70-year-old woman with
stage I breast cancer was 0.44, 0.25, or 0.10 QALYs,
respectively. The respective maximum absolute benefit
at age 40, 50, 60, or 70 for a woman with stage II
Table 4 Expected Incidence of Contralateral Breast Cancer (CBC) by Degree of Family History of Breast Cancer
Patient and Disease Characteristics No. of CBCs/1000 women over 10 years
No Family History Breast Cancer in a
Second-Degree Relative
Breast Cancer in a First-Degree Relative
Unilateral Bilateral
Age (years) ER Status Stage No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ No CPM CPM Δ
40 Positive I 46 2 44 59 3 56 86 4 82 158 9 149
40 Negative I 58 3 55 74 4 70 108 6 102 193 10 183
40 Positive II 41 2 39 52 3 49 77 4 73 137 8 129
40 Negative II 49 2 47 64 3 61 93 5 88 169 9 160
40 Positive III 29 2 27 36 2 34 54 3 51 98 5 93
40 Negative III 36 2 34 46 2 44 67 3 64 121 7 114
50 Positive I 46 2 44 59 3 56 86 5 81 154 8 146
50 Negative I 57 3 54 73 4 69 107 6 101 191 11 180
50 Positive II 40 2 38 51 2 49 75 3 72 134 7 127
50 Negative II 49 2 47 63 3 60 92 5 87 166 9 157
50 Positive III 28 1 27 36 2 34 53 3 50 95 5 90
50 Negative III 35 2 33 45 2 43 66 3 63 119 6 113
60 Positive I 45 2 43 57 3 54 83 4 79 152 8 144
60 Negative I 54 3 51 70 4 66 102 5 97 183 10 173
60 Positive II 38 2 36 49 2 47 72 4 68 132 7 125
60 Negative II 49 3 46 62 3 59 90 5 85 163 9 154
60 Positive III 28 1 27 36 2 34 53 3 50 95 5 90
60 Negative III 35 2 33 45 2 43 66 3 63 117 6 111
70 Positive I 41 2 39 53 3 50 77 4 73 141 8 133
70 Negative I 52 3 49 66 3 63 96 5 91 173 9 164
70 Positive II 36 2 34 47 3 44 68 4 64 121 7 114
70 Negative II 45 2 43 57 3 54 83 4 79 150 8 142
70 Positive III 26 1 25 34 1 33 50 2 48 89 4 85
70 Negative III 32 2 30 41 2 39 59 3 56 108 6 102
ER estrogen receptor, CPM contralateral prophylactic mastectomy, Δ, difference (No CPM-CPM); CBC risk reduction = 95% (base-case)
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primary breast cancer was 0.40, 0.28, 0.16, or 0.05
QALYs, and for a woman with a stage III primary breast
cancer was 0.14, 0.08, 0.03, or –0.03.
With all utilities set to 1 (i.e., without incorporating
quality of life in the analysis), the maximum absolute
difference in life expectancy was 0.77 life years when the
CPM benefit was 100 % and the annual probability of
developing a CBC was 1.68 % in women with a first-
degree relative with bilateral breast cancer. The results
were not sensitive to the first-year utility for CPM. For
example, a threshold analysis of the first-year utility for
CPM for a 40-year-old woman with stage I breast cancer
and no family history of breast cancer indicated that a
first-year utility above 0.482 (compared with 0.90 for
a unilateral mastectomy) would always result in CPM
being the optimal preventative strategy. In the probabi-
listic sensitivity analysis for 40-year-old women with stage
I breast cancer and no family history of breast cancer,
100 % of the trials had more effective CPM than no CPM
irrespective of family history.
Discussion
CPM is performed most frequently among women with
a family history of breast cancer, BRCA1/2 mutation
status, and younger age at diagnosis [34–36]. The grea-
test gain in quality-adjusted life expectancy was among
women age 40 with an ER-negative, stage I breast cancer
and a first-degree relative with either a unilateral or
bilateral breast cancer. However, our modeling results
showed that for women age 50–60 with a stage I, II, or III
breast cancer, CPM had a minimal benefit on quality-
adjusted life expectancy among those with a unilateral,
first-degree or second-degree family history of breast
Table 5 10 and 20-year Overall and Disease-Free Survival Rate Differences by Degree of Family History of Breast Cancer
Patient and Disease
Characteristics
10 and 20-year absolute overall survival (OS) and disease-free survival (DFS) rate difference (%)
No Family History Breast Cancer IN A Second-
Degree Relative
Breast Cancer in a First-Degree Relative
Unilateral Bilateral
















40 Positive I 0.09 0.29 1.79 2.97 0.12 0.36 2.31 3.81 0.18 0.54 3.42 5.61 0.32 0.96 6.28 10.24
40 Negative I 0.12 0.35 2.22 3.73 0.14 0.43 2.83 4.76 0.21 0.65 4.18 6.97 0.43 1.21 7.74 12.59
40 Positive II 0.07 0.20 1.55 2.39 0.09 0.27 2.01 3.07 0.15 0.43 2.98 4.56 0.29 0.79 5.39 8.16
40 Negative II 0.09 0.27 1.91 2.92 0.12 0.36 2.47 3.77 0.17 0.50 3.65 5.54 0.35 0.94 6.75 10.09
40 Positive III 0.04 0.11 1.03 1.31 0.06 0.15 1.32 1.68 0.10 0.21 1.95 2.47 0.16 0.38 3.54 4.47
40 Negative III 0.07 0.17 1.32 1.69 0.09 0.20 1.70 2.15 0.12 0.29 2.43 3.08 0.21 0.52 4.42 5.54
50 Positive I 0.10 0.29 1.81 2.91 0.13 0.38 2.31 3.72 0.18 0.54 3.37 5.43 0.32 0.94 6.18 9.77
50 Negative I 0.14 0.36 2.22 3.59 0.17 0.46 2.83 4.59 0.26 0.69 4.20 6.75 0.45 1.18 7.69 12.17
50 Positive II 0.09 0.24 1.52 2.30 0.12 0.31 1.97 2.97 0.18 0.44 2.92 4.37 0.31 0.79 5.28 7.81
50 Negative II 0.13 0.30 1.92 2.88 0.15 0.38 2.47 3.70 0.20 0.52 3.56 5.31 0.36 0.92 6.45 9.57
50 Positive III 0.04 0.10 0.97 1.24 0.05 0.13 1.25 1.61 0.08 0.19 1.84 2.31 0.16 0.36 3.38 4.23
50 Negative III 0.07 0.13 1.25 1.56 0.08 0.17 1.62 2.02 0.12 0.25 2.40 2.97 0.22 0.47 4.34 5.34
60 Positive I 0.09 0.25 1.72 2.65 0.11 0.31 2.20 3.38 0.17 0.46 3.23 4.92 0.33 0.84 6.00 9.00
60 Negative I 0.11 0.30 2.08 3.16 0.15 0.39 2.75 4.13 0.22 0.58 4.03 6.06 0.40 1.04 7.38 10.97
60 Positive II 0.08 0.22 1.47 2.07 0.10 0.28 1.88 2.66 0.15 0.38 2.78 3.90 0.30 0.72 5.15 7.19
60 Negative II 0.08 0.20 1.88 2.64 0.11 0.26 2.37 3.33 0.14 0.36 3.44 4.82 0.28 0.69 6.32 8.75
60 Positive III 0.04 0.10 0.98 1.17 0.06 0.13 1.27 1.53 0.08 0.20 1.85 2.21 0.16 0.35 3.39 3.99
60 Negative III 0.07 0.15 1.26 1.51 0.09 0.18 1.62 1.94 0.15 0.31 2.39 2.86 0.24 0.49 4.28 5.04
Ygy6
70 Positive I 0.09 0.19 1.61 2.06 0.11 0.24 2.04 2.64 0.16 0.35 2.98 3.84 0.28 0.62 5.54 7.03
70 Negative I 0.12 0.23 2.01 2.58 0.14 0.29 2.57 3.29 0.21 0.42 3.74 4.78 0.37 0.75 6.83 8.64
70 Positive II 0.07 0.14 1.32 1.59 0.09 0.18 1.71 2.08 0.15 0.31 2.51 3.06 0.27 0.52 4.60 5.54
70 Negative II 0.08 0.18 1.65 2.03 0.10 0.23 2.12 2.58 0.17 0.37 3.11 3.79 0.31 0.67 5.70 6.85
70 Positive III 0.05 0.07 0.91 0.93 0.07 0.10 1.21 1.23 0.11 0.16 1.76 1.78 0.18 0.29 3.21 3.22
70 Negative III 0.05 0.10 1.08 1.12 0.06 0.13 1.40 1.46 0.09 0.17 2.06 2.12 0.18 0.30 3.80 3.86
ER estrogen receptor, Δ%, difference %; CBC risk reduction = 95% (base-case)
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Fig. 2 Boxplot comparisons of survival outcomes. a Life expectancy, b quality-adjusted life expectancy, c 20-year overall survival, and d 20-year
disease-free survival with and without contralateral prophylactic mastectomy (CPM) in relation to family history of breast cancer
Fig. 3 Predicted differences in quality-adjusted survival benefit by age, ER status, and family history of breast cancer. Quality-adjusted survival
benefit of CPM in women with stage I breast cancer in relation to age, ER status, and family history. ER estrogen receptor, QALY quality-adjusted
life year
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cancer. CPM had an unfavorable quality-adjusted life
expectancy for most subgroups of women age 70 with a
stage II–III, ER-positive or ER-negative breast cancer,
regardless of the degree of family history of breast cancer.
Familial history is thought to account for 15–20 % of all
breast cancers [5], suggesting that CPM will benefit only a
modest number of patients.
The determination of BRCA1/2 mutation status among
women with a personal history of breast cancer and a
strong family history of breast cancer has increased in
importance [37]. Life expectancy gains with CPM among
women with a highly penetrant BRCA mutation diagnosed
with breast cancer at age 50 has been estimated at 0.9 and
0.7 years for node-negative and node-positive disease,
respectively [11]. In our model, women age 40 with a stage
I (range 0.38–0.82) or stage II (range 0.28–0.65) breast
cancer with a first-degree family history of breast cancer
showed similar gains in life expectancy. Lester-Coll et al.
[10] conducted a decision analysis to evaluate women age
45 by tumor subtype and cancer stages I–III, and sug-
gested that CPM would not improve quality-adjusted life
expectancy for the majority of women; however, family
history was not included in their model. A biological
explanation for our finding may be forthcoming be-
cause there is a growing trend towards expanding
genetic testing in women with strong family histories
and early-onset breast cancer who are not BRCA1/2
mutation carriers to identify other germline breast
cancer susceptibility mutations, such as p53, PTEN,
PALB2, and CDH1 [38–40].
Fig. 4 Predicted differences in quality-adjusted survival benefit by age, ER status, and primary breast cancer stage in women with no family
history of breast cancer. Quality-adjusted survival benefit of CPM in women with no family history of breast cancer in relation to age, ER status,
and primary breast cancer stage. ER estrogen receptor, QALY quality-adjusted life year
Fig. 5 Sensitivity analysis of predicted differences in quality-adjusted survival. Quality-adjusted survival in 40-year-old women with stage I breast
cancer and various annual probabilities of developing contralateral breast cancer (CBC), in relation to family history and effectiveness of
contralateral prophylactic mastectomy (CPM). QALY quality-adjusted life year
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Although having a strong family history increases the
risk of CBC, a recent study comparing outcomes among
women age 41 or younger with breast cancer showed that
having a family history of breast cancer did not worsen
overall survival [41]. Arrington et al. [20] also argued that
the survival curve for long-term survivors approaches that
of the general population within 10 years. We showed that
the maximum 20-year absolute overall survival rate bene-
fit of CPM was 1.21 % for women with a family history of
a first-degree relative with bilateral breast cancer. These
results are consistent with prior decision models that have
not considered family history and have shown a less than
1 % 20-year overall survival benefit for CPM [7]. Despite
the minimal overall 20-year survival rate benefit of CPM,
we found that the 20-year absolute DFS rate benefit
ranged from 0.93 % in women with no family history to
12.59 % in women with a first-degree relative with a bilat-
eral breast cancer. Given the difference in magnitude for
the absolute 20-year overall and disease-free survival rate
benefit for CPM, additional information such as quality-
adjusted life expectancy should be considered in the
decision-making process and may ultimately play a signifi-
cant role in a woman’s decision of whether to have CPM.
Our decision model applied individual-level simulation
to compare quality-adjusted health outcomes of CPM
and surveillance only (no CPM). A strength of this ana-
lysis method was that it enabled us to estimate indivi-
dual patient outcomes, such as the development of a
CBC. As with all modeling studies, ours was subject to
several limitations. Although our model considered a
10-year time frame in which patients were at risk for
dying from the primary cancer, in reality breast cancer
patients remain at risk of dying from their breast cancer
after this time period, although the risk is reduced dras-
tically [30, 42, 43]. In our model we relied on probability
estimates obtained from the literature, particularly those
concerning the risk of CBC and utilities for health states.
Since the increased risk of CBC associated with ER-
negative cancers as it relates to family history is not
explicitly stated in the literature, our estimate of this risk
factor was based on a calibration of plausible CBC risk
ranges from reported data. Nevertheless, as expected,
sensitivity analysis showed an increase in the benefit of
CPM as the risk of CBC increases. Although health state
utilities are dependent on the method used to obtain
them, a consistent theme has emerged in the literature
for prophylactic mastectomy. Studies have shown that
women report negative feelings regarding body image
[44] and adverse psychosocial outcomes following CPM
which may not be accounted for in utilities available in
the literature [45, 46], which we relied on. However,
beyond the initial year after surgery, utilities for CPM
are not significantly different from utilities for primary
mastectomy [47]. In addition, a recent study showed that
perceptions of CBC risk attenuated over time for both
CPM and non-CPM patients [48].
Conclusion
CPM reduces the risk of CBC and is associated with a gain
in quality-adjusted life expectancy and disease-free survival
in younger women who have an early-stage breast cancer
and a history of breast cancer in first-degree relatives. How-
ever, even in this subgroup, CPM offers only a minimal
overall survival advantage and the long-term psychosocial
outcomes are unclear. Patients with ER-negative breast
cancer consistently have a higher gain in quality-adjusted
life expectancy than patients with ER-positive cancer, and
this highlights the importance of anti-estrogen therapy
as an alternative strategy for CPM among women with
ER-positive breast cancer. Because patients are concerned
about their lifetime experience of cancer, specifically driven
by fear of developing a second cancer in the unaffected
breast [49], quality of life and psychosocial considerations
should be considered along with these clinical factors in
surgical decision-making regarding CPM.
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